NCT00681369已完成不适用
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 217
- 主要终点
- Evaluate Faslodex therapeutic strategy and treatment duration
研究概览
简要总结
the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
排除标准
- 未提供
结局指标
主要结局
Evaluate Faslodex therapeutic strategy and treatment duration
时间窗: At the end of the study
Describe the characteristics of patients treated with Faslodex
时间窗: At the end of the study
次要结局
未报告次要终点
研究者
相似试验
终止
不适用
Faslodex Observations During Regular Use by Advanced Mammacarcinoma PatientsBreast CancerNCT00241462AstraZeneca150
已完成
不适用
Faslodex Specific Clinical Experience InvestigationBreast CancerNCT01501266AstraZeneca660
已完成
不适用
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)Malignant Neoplasm of Breast Stage IVNCT01509625Isabel Blancas272
已完成
不适用
Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)Breast CancerNCT00880711AstraZeneca57
已完成
不适用
A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast CancerPostmenopauseBreast CancerNCT01171417AstraZeneca570